190 related articles for article (PubMed ID: 30726838)
21. Adverse events of Dupilumab in adults with moderate-to-severe atopic dermatitis: A meta-analysis.
Ou Z; Chen C; Chen A; Yang Y; Zhou W
Int Immunopharmacol; 2018 Jan; 54():303-310. PubMed ID: 29182975
[TBL] [Abstract][Full Text] [Related]
22. Spotlight on dupilumab in the treatment of atopic dermatitis: design, development, and potential place in therapy.
D'Erme AM; Romanelli M; Chiricozzi A
Drug Des Devel Ther; 2017; 11():1473-1480. PubMed ID: 28553077
[TBL] [Abstract][Full Text] [Related]
23. Dupilumab, A Monoclonal Antibody for Atopic Dermatitis: A Review of Current Literature.
Blakely K; Gooderham M; Papp K
Skin Therapy Lett; 2016 Mar; 21(2):1-5. PubMed ID: 27223113
[TBL] [Abstract][Full Text] [Related]
24. Onset of Schamberg Disease and Resolution of Alopecia Areata During Treatment of Atopic Dermatitis With Dupilumab.
Szekely S; Vaccari D; Salmaso R; Belloni-Fortina A; Alaibac M
J Investig Allergol Clin Immunol; 2021 Feb; 31(1):65-66. PubMed ID: 32490817
[No Abstract] [Full Text] [Related]
25. Efficacy of dupilumab for controlling severe atopic dermatitis with dominant-negative CARD11 variant.
Charvet E; Bourrat E; Hickman G; Donadieu J; Bellanné-Chantelot C; Jachiet M; Bouaziz JD; Bagot M; Cassius C
Clin Exp Dermatol; 2021 Oct; 46(7):1334-1335. PubMed ID: 33864281
[No Abstract] [Full Text] [Related]
26. Dupilumab in the treatment of moderate-to-severe atopic dermatitis.
Kraft M; Worm M
Expert Rev Clin Immunol; 2017 Apr; 13(4):301-310. PubMed ID: 28165826
[TBL] [Abstract][Full Text] [Related]
27. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial.
Blauvelt A; de Bruin-Weller M; Gooderham M; Cather JC; Weisman J; Pariser D; Simpson EL; Papp KA; Hong HC; Rubel D; Foley P; Prens E; Griffiths CEM; Etoh T; Pinto PH; Pujol RM; Szepietowski JC; Ettler K; Kemény L; Zhu X; Akinlade B; Hultsch T; Mastey V; Gadkari A; Eckert L; Amin N; Graham NMH; Pirozzi G; Stahl N; Yancopoulos GD; Shumel B
Lancet; 2017 Jun; 389(10086):2287-2303. PubMed ID: 28478972
[TBL] [Abstract][Full Text] [Related]
28. Off-label use of dupilumab for the treatment of moderate to severe atopic dermatitis in children aged below 6 years of age: a case series.
Da J; Ali K; Lu K; Lou H; Qiu Y; Shan J; Wu L
Clin Exp Dermatol; 2022 Feb; 47(2):423-425. PubMed ID: 34482550
[No Abstract] [Full Text] [Related]
29. Real-world persistence with dupilumab among adults with atopic dermatitis.
Silverberg JI; Guttman-Yassky E; Gadkari A; Kuznik A; Mallya UG; Mastey V; Zhang H; Chen Z; Chen C; Korotzer A; Sierka D; Fenton MC; Kaur M; Jalbert JJ
Ann Allergy Asthma Immunol; 2021 Jan; 126(1):40-45. PubMed ID: 32739313
[TBL] [Abstract][Full Text] [Related]
30. Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis.
Simpson EL; Bieber T; Guttman-Yassky E; Beck LA; Blauvelt A; Cork MJ; Silverberg JI; Deleuran M; Kataoka Y; Lacour JP; Kingo K; Worm M; Poulin Y; Wollenberg A; Soo Y; Graham NM; Pirozzi G; Akinlade B; Staudinger H; Mastey V; Eckert L; Gadkari A; Stahl N; Yancopoulos GD; Ardeleanu M;
N Engl J Med; 2016 Dec; 375(24):2335-2348. PubMed ID: 27690741
[TBL] [Abstract][Full Text] [Related]
31. Effectiveness and safety of dupilumab for atopic dermatitis in a liver transplant recipient: a case report.
Ludriksone L; Elsner P; Malessa C; Settmacher U; Schliemann S
J Dtsch Dermatol Ges; 2020 Jul; 18(7):740-742. PubMed ID: 32212242
[No Abstract] [Full Text] [Related]
32. Successful use of dupilumab for the treatment of atopic dermatitis on the genitals, a neglected anatomical site.
Paolino G; Sernicola A; Di Nicola MR; Foti A; Brianti P; Vaira F; Grieco T; Mercuri SR
Clin Exp Dermatol; 2022 Jan; 47(1):176-178. PubMed ID: 34398987
[TBL] [Abstract][Full Text] [Related]
33. Improvement of atopic dermatitis with dupilumab occurs equally well across different anatomical regions: data from phase III clinical trials.
Blauvelt A; Rosmarin D; Bieber T; Simpson EL; Bagel J; Worm M; Deleuran M; Katoh N; Kawashima M; Shumel B; Chen Z; Rossi AB; Hultsch T; Ardeleanu M
Br J Dermatol; 2019 Jul; 181(1):196-197. PubMed ID: 30719707
[No Abstract] [Full Text] [Related]
34. Dupilumab: human monoclonal antibody against IL-4Rα for moderate to severe atopic dermatitis.
Paton DM
Drugs Today (Barc); 2017 Sep; 53(9):477-487. PubMed ID: 29238761
[TBL] [Abstract][Full Text] [Related]
35. Aarskog-Scott syndrome and atopic dermatitis successfully treated with dupilumab: a casual presentation?
Calabrese G; Licata G; Buononato D; Gambardella A; De Rosa A; Argenziano G
Clin Exp Dermatol; 2022 Feb; 47(2):452-453. PubMed ID: 34482546
[No Abstract] [Full Text] [Related]
36. Two cases of psoriasiform dermatitis arising during dupilumab therapy and successfully treated with delgocitinib ointment.
Kurihara K; Fujiyama T; Tokura Y; Honda T
Eur J Dermatol; 2021 Oct; 31(5):658-660. PubMed ID: 34704949
[No Abstract] [Full Text] [Related]
37. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ).
de Bruin-Weller M; Thaçi D; Smith CH; Reich K; Cork MJ; Radin A; Zhang Q; Akinlade B; Gadkari A; Eckert L; Hultsch T; Chen Z; Pirozzi G; Graham NMH; Shumel B
Br J Dermatol; 2018 May; 178(5):1083-1101. PubMed ID: 29193016
[TBL] [Abstract][Full Text] [Related]
38. [Ocular symptoms associated with dupilumab in atopic dermatitis].
Voorberg AN; Oosterhaven JAF; Wijdh RHJ; de Bruin-Weller MS; Schuttelaar MLA
Ned Tijdschr Geneeskd; 2019 Mar; 163():. PubMed ID: 30945835
[TBL] [Abstract][Full Text] [Related]
39. Dupilumab: A review of its use in the treatment of atopic dermatitis.
Gooderham MJ; Hong HC; Eshtiaghi P; Papp KA
J Am Acad Dermatol; 2018 Mar; 78(3 Suppl 1):S28-S36. PubMed ID: 29471919
[TBL] [Abstract][Full Text] [Related]
40. Dupilumab for treatment of atopic dermatitis.
Seegräber M; Srour J; Walter A; Knop M; Wollenberg A
Expert Rev Clin Pharmacol; 2018 May; 11(5):467-474. PubMed ID: 29557246
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
